Ipsen to buy liver disease drugmaker for $952M


Ipsen is set to acquire Albireo Pharma Inc., the rare liver disease-focused biopharma spun out of AstraZeneca in 2008, for about $952 million.

Previous Local stock index fell last year. But these five St. Louis-area stocks did great.
Next Rumble Boxing hits Minneapolis' North Loop neighborhood